Clinical Trial Update: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients [Phase 2]

View source ↗

Summary

Phase 2 extension study results for safety and efficacy of eculizumab in patients with paroxysmal nocturnal hemoglobinuria have been completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2019-07-12